CPT code 0007U designates a Proprietary Laboratory Analyses (PLA) test for ToxProtect by Genotox Laboratories LTD: a combined presumptive urine drug screen with confirmatory testing for detected drugs plus DNA analysis of a buccal swab to authenticate the urine source. This PLA code is notable because it maps to a single manufacturer's test, which has implications for billing clarity, payer policy, and clinical documentation when source verification is required.

Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides an overview of common payer coverage considerations, typical sites of service for collection and processing, and the clinical context in which source-authenticated toxicology testing is used.

Readers will learn what CPT code 0007U represents, why PLA codes matter for lab billing and prior authorization workflows, and how this combined toxicology-and-DNA test differs from standard drug screens. The report summarizes available benchmarking and policy themes relevant to lab providers and payers, highlights documentation and specimen requirements typically associated with source authentication testing, and identifies where additional payer-specific guidance or prior authorization may be expected. Data not available in the input will be flagged where applicable.